- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, July 24, 2020
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by Devex cited a study published in the February 2018 issue of The American Journal of Managed Care® (AJMC®), titled “Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?.” The study found that the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
An article by Washington Examiner referenced a piece published on AJMC.com, the website of AJMC®. The piece, “Caution Strongly Recommended When Using Chloroquine, Hydroxychloroquine in Patients With Cardiovascular Disease, COVID-19,” indicated that despite positive results seen from the use of chloroquine and hydroxychloroquine in some patients hospitalized with coronavirus disease 2019 (COVID-19), concern is mounting about how these drugs affect patients’ cardiovascular health, specifically the heart.
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
April 16th 2025A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.
Read More
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More
